Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes

The antihyperglycemic agent linagliptin, a dipeptidyl peptidase-4 (DPP-IV) inhibitor, has been shown to reduce inflammation and improve endothelial cell function. In this study, we hypothesized that DPP-IV inhibition with linagliptin would improve impaired cerebral perfusion in diabetic rats, as wel...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Physiol Regul Integr Comp Physiol
Asıl Yazarlar: Hardigan, Trevor, Yasir, Abdul, Abdelsaid, Mohammed, Coucha, Maha, El-Shaffey, Sally, Li, Weiguo, Johnson, Maribeth H., Ergul, Adviye
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Physiological Society 2016
Konular:
Obesity, Diabetes and Energy Homeostasis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142225/
https://ncbi.nlm.nih.gov/pubmed/27357799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpregu.00057.2016
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller